Endpoints News 8. Jan. 2026 FDA staff cuts mostly didn't impact new drug review timelines, analysis finds
Endpoints News 8. Jan. 2026 Secretive Rampart Bioscience closes after pursuing non-viral gene therapy
Endpoints News 8. Jan. 2026 Ollin’s drug clears retinal disease better than Roche’s Vabysmo in Phase 1b trial
Endpoints News 8. Jan. 2026 French biotech Enodia gets €20.7M aided by Pfizer for protein degrader work
Endpoints News 8. Jan. 2026 Charles Fuchs leaves Roche to steer ADC pipeline at Tubulis shortly after $401M Series C
Endpoints News 8. Jan. 2026 Diagonal Therapeutics secures $125M in Series B co-led by Sanofi Ventures
Endpoints News 8. Jan. 2026 Former Genentech leaders’ protein degrader startup EpiBiologics nets $107M
Endpoints News 7. Jan. 2026 Immuneering’s pancreatic cancer pill continues to beat standard care, updated first line data show